EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

TARBP2 facilitates renal cell carcinoma immune escape by suppressing 53BP1 phase separation to upregulate B7-H3

Minyu Chen, Mingjie Lin, Jiangquan Zhu, Kezhi Liu, Guannan Shu, Zhuting Tong, Mi Zhou, Liangmin Fu, Taowei Yang, Yihui Pan, Xinwei Zhou, Jinchen Luo und 9 weitere

Journal of Clinical Investigation · 02.11.2026 · 136 (21)

DOI: 10.1172/jci199525 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 02.11.2026. Verfasst von Minyu Chen und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. Hauptthemen laut MEDLINE: RNA-Binding Proteins, Carcinoma, Renal Cell, Kidney Neoplasms, Tumor Escape. Die Arbeit nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Hunan Province, Natural Science Foundation of Jiangsu Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Renal cell carcinoma (RCC) harbors an immunosuppressive tumor microenvironment that facilitates immune evasion and resistance to immune checkpoint blockade (ICB). However, the factors driving immune escape in RCC remain incompletely understood. In this study, transactivation response RNA-binding protein 2 (TARBP2) was identified as a critical regulator of the immune checkpoint molecule B7-H3. Elevated TARBP2 expression was associated with poor prognosis and ICB resistance in patients with RCC. Functionally, TARBP2 in RCC cells suppressed the intratumoral accumulation and cytotoxicity of T cells, particularly NK cells, thereby promoting immune escape. Mechanistically, nuclear TARBP2 interacted with p53-binding protein 1 (53BP1), inhibiting 53BP1 phase separation and subsequent p53 activation, thereby augmenting B7-H3 transcription. Furthermore, TARBP2 inhibition significantly enhanced ICB efficacy when combined with adoptive NK cell therapy. Collectively, these findings establish TARBP2 as a key mediator of immune evasion in RCC and a promising therapeutic target for overcoming ICB resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA-Binding ProteinsCarcinoma, Renal CellKidney NeoplasmsTumor EscapeB7 AntigensTumor Suppressor p53-Binding Protein 1Neoplasm ProteinsHumansAnimalsTrans-Activation Responsive RNA-Binding ProteinKiller Cells, NaturalMiceCell Line, TumorImmunoediting, Cancer

Stichwörter der Autor:innen

Cancer immunotherapyImmunologyNK cellsOncogenesOncology

Substanzen

RNA-Binding ProteinsB7 AntigensTumor Suppressor p53-Binding Protein 1Trans-Activation Responsive RNA-Binding ProteinCD276 protein, humanTP53BP1 protein, humanNeoplasm Proteins

Autor:innen und Institutionen

  • Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
  • Department of Urology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
  • Department of Urology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangdong Provincial Clinical Research Center for Child Health, Guangzhou, China.
  • Department of Radiation Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
  • Department of Oncology and Southwest Cancer Center, Southwest Hospital of The Third Military Medical University (Army Medical University), Chongqing, China.
  • Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, China.

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Hunan Province
  • Natural Science Foundation of Jiangsu Province
  • Natural Science Foundation of Guangdong Province
  • Medical Scientific Research Foundation of Guangdong Province of China
  • China Postdoctoral Science Foundation

Zitieren

APA

Chen, M., Lin, M., Zhu, J., Liu, K., Shu, G., Tong, Z., Zhou, M., Fu, L., Yang, T., Pan, Y., Zhou, X., Luo, J., Liao, W., Li, Q., Liao, L., Lin, H., Huang, K., Zhang, L., Chen, W., …, & Zhang, J. (2026). TARBP2 facilitates renal cell carcinoma immune escape by suppressing 53BP1 phase separation to upregulate B7-H3. Journal of Clinical Investigation, 136(21). https://doi.org/10.1172/jci199525

Vancouver

Chen M, Lin M, Zhu J, Liu K, Shu G, Tong Z, et al. TARBP2 facilitates renal cell carcinoma immune escape by suppressing 53BP1 phase separation to upregulate B7-H3. Journal of Clinical Investigation. 2026;136(21). doi:10.1172/jci199525

BibTeX
@article{Chen2026,
  author = {Chen, Minyu and Lin, Mingjie and Zhu, Jiangquan and Liu, Kezhi and Shu, Guannan and Tong, Zhuting and Zhou, Mi and Fu, Liangmin and Yang, Taowei and Pan, Yihui and Zhou, Xinwei and Luo, Jinchen and Liao, Wuyuan and Li, Qihao and Liao, Lican and Lin, Hansen and Huang, Kangbo and Zhang, Lizhen and Chen, Wei and Luo, Junhang and Zhang, Jiaxing},
  title = {TARBP2 facilitates renal cell carcinoma immune escape by suppressing 53BP1 phase separation to upregulate B7-H3},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  volume = {136},
  number = {21},
  doi = {10.1172/jci199525}
}
Kostenlos starten →